Literature DB >> 12173320

Fas (CD95/APO-1) and Fas ligand expression in normal pancreas and pancreatic tumors. Implications for immune privilege and immune escape.

Wolfram V Bernstorff1, Jonathan N Glickman, Robert D Odze, Francis A Farraye, Hong G Joo, Peter S Goedegebuure, Timothy J Eberlein.   

Abstract

BACKGROUND: Fas (CD95/APO-1) and Fas ligand (FasL) play key roles in immunologic homeostasis and immune privilege and may regulate normal cell turnover. Earlier studies had suggested that FasL-positive pancreatic carcinoma cell lines can induce apoptosis in T cells, thereby evading host immune surveillance. In the current study the authors have characterized the expression of Fas and FasL in the normal pancreas and in pancreatic neoplasia.
METHODS: Pancreatic resection specimens with ductal-type adenocarcinoma or intraductal dysplasia (n = 41), nonductal pancreatic neoplasms (n = 5), and chronic pancreatitis (n = 4) were examined for Fas and FasL expression by immunohistochemistry. The results in invasive adenocarcinoma were compared to those for benign ducts and intraductal dysplasia, and correlated with clinicopathologic features of the tumors and with patient survival.
RESULTS: Fas was expressed in the normal pancreatic ducts and in intraductal dysplasia in a mixed membrane/cytoplasmic pattern. In all cases of invasive ductal-type adenocarcinoma, membranous Fas could not be detected; cytoplasmic Fas staining was reduced or completely lost. Loss of Fas expression in pancreatic ductal-type adenocarcinomas significantly correlated with poorer differentiation and extrapancreatic spread of the tumors and was associated with a shorter overall survival. FasL expression was present in the normal pancreatic ducts as well as in islet cells and was maintained in all pancreatic tumors.
CONCLUSIONS: These results implicate the Fas pathway in the regulation of physiologic cell turnover and immune privilege in the normal pancreas and indicate that loss of Fas expression is correlated with malignant transformation and biologic aggressiveness in pancreatic adenocarcinomas. This may represent a mechanism by which pancreatic tumor cells become resistant to apoptosis and escape immune surveillance in vivo.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12173320     DOI: 10.1002/cncr.10549

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  21 in total

1.  Tissue expression of the proteins fas and fas ligand in colorectal cancer and liver metastases.

Authors:  Stylianos Kykalos; Spuridon Mathaiou; Anastasios J Karayiannakis; Dimitris Patsouras; Maria Lambropoulou; Constantinos Simopoulos
Journal:  J Gastrointest Cancer       Date:  2012-06

2.  Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer.

Authors:  X Zhang; X Miao; T Sun; W Tan; S Qu; P Xiong; Y Zhou; D Lin
Journal:  J Med Genet       Date:  2005-06       Impact factor: 6.318

Review 3.  Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies.

Authors:  Kristin G Anderson; Ingunn M Stromnes; Philip D Greenberg
Journal:  Cancer Cell       Date:  2017-03-13       Impact factor: 31.743

4.  Are Sertoli cells a kind of mesenchymal stem cells?

Authors:  Daoyuan Gong; Chunfu Zhang; Tao Li; Jiahui Zhang; Nannan Zhang; Zehua Tao; Wei Zhu; Xiaochun Sun
Journal:  Am J Transl Res       Date:  2017-03-15       Impact factor: 4.060

5.  Phosphatidylserine receptor in chronic pancreatitis: evidence for a macrophage independent role.

Authors:  Jörg Köninger; Peter Balaz; Markus Wagner; Xin Shi; Igor Cima; Arthur Zimmermann; Pierluigi di Sebastiano; Markus W Büchler; Helmut Friess
Journal:  Ann Surg       Date:  2005-01       Impact factor: 12.969

6.  Database of mRNA gene expression profiles of multiple human organs.

Authors:  Chang Gue Son; Sven Bilke; Sean Davis; Braden T Greer; Jun S Wei; Craig C Whiteford; Qing-Rong Chen; Nicola Cenacchi; Javed Khan
Journal:  Genome Res       Date:  2005-03       Impact factor: 9.043

7.  Expression and prognostic value of c-Myc and Fas (CD95/APO1) in patients with pancreatic cancer.

Authors:  Chengzhi He; Hua Jiang; Shasha Geng; Haihui Sheng; Xiaoying Shen; Xiaoyan Zhang; Shizhang Zhu; Ximei Chen; Changqing Yang; Hengjun Gao
Journal:  Int J Clin Exp Pathol       Date:  2014-01-15

8.  Examination of apoptosis signaling in pancreatic cancer by computational signal transduction analysis.

Authors:  Felix Rückert; Gihan Dawelbait; Christof Winter; Arndt Hartmann; Axel Denz; Ole Ammerpohl; Michael Schroeder; Hans Konrad Schackert; Bence Sipos; Günter Klöppel; Holger Kalthoff; Hans-Detlev Saeger; Christian Pilarsky; Robert Grützmann
Journal:  PLoS One       Date:  2010-08-19       Impact factor: 3.240

9.  Detrimental role of CC chemokine receptor 4 in murine polymicrobial sepsis.

Authors:  Tobias Traeger; Wolfram Kessler; Volker Assfalg; Katharina Cziupka; Pia Koerner; Constanze Dassow; Katrin Breitbach; Marlene Mikulcak; Ivo Steinmetz; Klaus Pfeffer; Claus-Dieter Heidecke; Stefan Maier
Journal:  Infect Immun       Date:  2008-09-02       Impact factor: 3.441

10.  Increasing transplant mass results in long-term allograft survival and recovery from transplant vasculopathy.

Authors:  De Shon Hall; Edda M Roberts; Sharon Ferguson; Zhuangzhi Wang; Joanna D Davies
Journal:  J Clin Immunol       Date:  2003-05       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.